Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC 707545) in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2013
At a glance
- Drugs Alvespimycin (Primary)
- Indications Breast cancer; Colon cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cancer
- Focus Adverse reactions
- 22 Dec 2009 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Feb 2008 Kosan has reported that this trial is to be discontinued.